H 1307 (replaced by S 771) – MassachusettsStatus: Inactive / Dead
Year Introduced: 2021
Relative to the manufacture of generic prescription drugs by the Commonwealth. The study shall examine the factors that most greatly contribute to increasing drug costs in the commonwealth, the ways in which the cost of generic prescription drugs factors into MassHealth spending and healthcare costs across the Massachusetts healthcare system and whether establishing a state-run generic prescription drug brand manufacturing program would be reasonable and effective at reducing drug prices and the cost of healthcare in Massachusetts including, but not limited to: (i) factors that contribute towards the increase of generic prescription drug prices; (ii) identifying generic prescription drugs that comprise the greatest proportion of generic prescription drug spending; (iii) identifying generic prescription drugs that comprise the greatest proportion of generic prescription drug price increases; (iv) the competitive landscape of generic drug manufacturing and its effects on generic prescription drugs prices in Massachusetts; (v) the degree of competition in regards to the generic prescription drugs that comprise the greatest degree of spending; and (vi) the potential impact on prescription drug costs and healthcare costs by establishing a state-run program to manufacture generic prescription drugs.
Return to Database Search
© 2018-2019 The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.